Today: 28 June 2026
Browse Category

Biotechnology 9 December 2025 - 17 December 2025

Twist Bioscience (TWST) Stock News Today: Latest Catalysts, Analyst Forecasts, and 2026 Outlook (Dec. 17, 2025)

Twist Bioscience (TWST) Stock News Today: Latest Catalysts, Analyst Forecasts, and 2026 Outlook (Dec. 17, 2025)

Twist Bioscience shares rose about 6% to $33 by late morning Dec. 17 after new partnership news, recent product launches, and a Barclays price target hike to $39. The company signed a licensing deal with Aptamer Group for use in PCR and NGS products and launched new plasmid DNA preps. Investors are watching progress toward breakeven targeted for fiscal Q4 2026.
17 December 2025
··
Aditxt (ADTX) Stock Surges After Proxy Filing Sets Up Reverse Split Vote and “bitXbio” Name Change — What to Know on Dec. 17, 2025

Aditxt (ADTX) Stock Surges After Proxy Filing Sets Up Reverse Split Vote and “bitXbio” Name Change — What to Know on Dec. 17, 2025

Aditxt shares surged late December 17 after the company filed a definitive proxy for a January 30, 2026, special shareholder meeting. The agenda includes votes on potential share dilution, a reverse stock split, and a rebrand to “bitXbio, Inc.” Traders responded to the capital structure moves, not clinical news.
17 December 2025
··
Structure Therapeutics (GPCR) Stock: Why Shares Are Sliding on Dec. 16, 2025 After Breakout Obesity Pill Data and a $747.5M Offering

Structure Therapeutics (GPCR) Stock: Why Shares Are Sliding on Dec. 16, 2025 After Breakout Obesity Pill Data and a $747.5M Offering

Structure Therapeutics shares fell about 6% to $60.73 Tuesday, swinging between $58.95 and $65.69 intraday after recent gains. The drop followed positive Phase 2b results for its oral obesity drug aleniglipron and a $747.5 million equity raise. Trading volume was below average, with some reports noting declines up to 9% during the session.
16 December 2025
···
Corcept Therapeutics (CORT) Stock Drops on Dec. 16, 2025: UBS Neutral Call, Relacorilant FDA Catalyst, and Updated Price Targets

Corcept Therapeutics (CORT) Stock Drops on Dec. 16, 2025: UBS Neutral Call, Relacorilant FDA Catalyst, and Updated Price Targets

Corcept Therapeutics shares fell 9% to $79.44 on December 16, 2025, after UBS initiated coverage at Neutral with a $95 target, citing valuation concerns. The stock had surged about 75% year-to-date. No major clinical or regulatory news drove the drop. Trading volume reached approximately 1.27 million shares.
16 December 2025
···
Wave Life Sciences (WVE) Stock News Today: Oppenheimer Lifts Target to $32 as WVE-007 Obesity Data Fuels Volatility

Wave Life Sciences (WVE) Stock News Today: Oppenheimer Lifts Target to $32 as WVE-007 Obesity Data Fuels Volatility

Wave Life Sciences shares rose 5.2% to $16.94 Tuesday after Oppenheimer raised its price target to $32, citing positive interim Phase 1 data for obesity drug WVE-007. The company reported a 9.4% reduction in visceral fat and a 3.2% increase in lean mass at three months after a single dose. Placebo participants saw no significant changes. Wave’s trial enrolled over 100 adults with BMI 28–35.
16 December 2025
··
uniQure (QURE) Stock Jumps in Pre-Market on Dec. 16, 2025: FDA AMT-130 Uncertainty, Analyst Price Targets, and Key Catalysts Ahead

uniQure (QURE) Stock Jumps in Pre-Market on Dec. 16, 2025: FDA AMT-130 Uncertainty, Analyst Price Targets, and Key Catalysts Ahead

uniQure shares jumped about 15% to $23.50 in pre-market trading Dec. 16 after a 10% after-hours gain, despite ongoing FDA uncertainty over its Huntington’s disease gene therapy, AMT-130. The FDA told uniQure its Phase I/II data are “currently unlikely” to support a Biologics License Application, prompting the company to seek further talks in early 2026.
16 December 2025
··
Immunome (IMNM) Stock Today: Phase 3 RINGSIDE Win, $400M Offering, and Fresh Analyst Targets (Dec. 16, 2025)

Immunome (IMNM) Stock Today: Phase 3 RINGSIDE Win, $400M Offering, and Fresh Analyst Targets (Dec. 16, 2025)

Immunome reported positive Phase 3 results for varegacestat in desmoid tumors, showing an 84% reduction in risk of progression or death versus placebo. The company also announced a proposed $400 million stock offering, raising concerns about dilution. Most side effects were mild, but 55.6% of premenopausal women experienced ovarian toxicity. Shares moved sharply on the news.
16 December 2025
··
Immunovant (IMVT) Stock News and Forecast for Dec. 14, 2025: $550M Financing Closes, Roivant Buys $350M, Analysts Update Targets

Immunovant (IMVT) Stock News and Forecast for Dec. 14, 2025: $550M Financing Closes, Roivant Buys $350M, Analysts Update Targets

Immunovant closed a $550 million stock offering on December 12, 2025, selling 26.2 million shares at $21 each. Roivant Sciences bought 16.7 million shares, investing about $350 million and increasing its stake. IMVT shares ended the week at $26.42, up 6.6% after heavy trading. The company plans to use proceeds to fund clinical trials and general operations.
14 December 2025
·
Amicus Therapeutics (FOLD) Stock News, Forecasts and Analyst Outlook on Dec. 14, 2025: What’s Driving the Rally?

Amicus Therapeutics (FOLD) Stock News, Forecasts and Analyst Outlook on Dec. 14, 2025: What’s Driving the Rally?

Amicus Therapeutics shares closed at $10.55 Friday, up 6.6% after hitting a 52-week high of $10.85. Renewed bullish analyst coverage, including a Zacks “strong buy” and a mean price target of $15.90, followed the move. The company’s profitability trajectory and recent earnings have drawn increased attention from investors.
14 December 2025
··
CSL Limited Stock (ASX:CSL) Update: Hemgenix 5-Year Data, Vaccine Audit Fallout, Buyback Support — Week Ahead Outlook (Updated 14 Dec 2025)

CSL Limited Stock (ASX:CSL) Update: Hemgenix 5-Year Data, Vaccine Audit Fallout, Buyback Support — Week Ahead Outlook (Updated 14 Dec 2025)

CSL shares closed Friday at A$183.93, up 2.86% on the day but down 0.85% for the week. The company reported five-year data for its hemophilia B gene therapy HEMGENIX, showing 94% of patients remained free from continuous treatment. Investors also weighed scrutiny of CSL Seqirus vaccine deals and the ongoing A$750 million buyback.
14 December 2025
··
Vertex Pharmaceuticals (VRTX) Stock: This Week’s News, Analyst Forecasts, and the Week-Ahead Outlook (Updated Dec. 12, 2025)

Vertex Pharmaceuticals (VRTX) Stock: This Week’s News, Analyst Forecasts, and the Week-Ahead Outlook (Updated Dec. 12, 2025)

Vertex Pharmaceuticals shares closed at $452.04 Friday, up 2.26% for the week after rebounding from early losses. The move followed new pediatric data for CASGEVY, showing children ages 5–11 with sickle cell disease remained crisis-free for at least 12 months. Vertex plans global regulatory submissions in 2026. One beta thalassemia patient died from pre-transplant chemotherapy complications.
13 December 2025
··
Geron Stock (NASDAQ: GERN) News Today: Restructuring, Analyst Ratings, and 2026 Catalysts (Dec. 12, 2025)

Geron Stock (NASDAQ: GERN) News Today: Restructuring, Analyst Ratings, and 2026 Catalysts (Dec. 12, 2025)

Geron Corporation shares fell 5% to $1.32 on Dec. 12 after the company announced plans to cut about one-third of its 260-person workforce. The restructuring aims to lower 2026 expenses and focus resources on RYTELO’s commercial growth. Analysts maintained a neutral stance as RYTELO’s Q3 revenue slipped 3% quarter-over-quarter to $47.2 million.
12 December 2025
··
Applied Therapeutics (APLT) Stock News Today: Cycle Deal Details, CVR Upside, and Analyst Outlook (Dec. 12, 2025)

Applied Therapeutics (APLT) Stock News Today: Cycle Deal Details, CVR Upside, and Analyst Outlook (Dec. 12, 2025)

Applied Therapeutics shares fell about 35% premarket to $0.14 after announcing a deal to be acquired by Cycle Pharmaceuticals. The offer includes $0.088 per share in cash and a non-transferable contingent value right tied to future FDA approvals and sales milestones. The transaction is expected to close in Q1 2026, pending a majority tender. No financing condition is attached to the merger.
12 December 2025
···
10x Genomics (TXG) Stock: Citi Downgrade, AI Partnerships and 2026 Forecast After December 11 Sell-Off

10x Genomics (TXG) Stock: Citi Downgrade, AI Partnerships and 2026 Forecast After December 11 Sell-Off

10x Genomics shares fell over 6% to the mid-$16 range on December 11, 2025, after Citigroup downgraded the stock from Buy to Neutral, maintaining an $18 price target. The company’s market cap stands near $2.2 billion. Despite the drop, shares remain up more than 20% year to date. Analyst consensus now leans Hold, with average 12-month price targets around $15–17.
11 December 2025
····
Wave Life Sciences (WVE) Stock on December 11, 2025: Obesity Breakthrough, 180% Rally, $350M Offering and Fresh Analyst Targets

Wave Life Sciences (WVE) Stock on December 11, 2025: Obesity Breakthrough, 180% Rally, $350M Offering and Fresh Analyst Targets

Wave Life Sciences shares surged over 180% in a week after Phase 1 data showed its obesity drug WVE-007 reduced visceral fat by up to 10% and increased lean mass. The stock hit a five-year high near $22 before retreating to $17.06 following a $350 million equity offering and insider selling. Analyst price targets jumped, but Wave remains unprofitable with high valuation risk.
11 December 2025
···
Arrowhead Pharmaceuticals (ARWR) Stock Near 52‑Week High After FDA Approval and New Alzheimer’s Trial: Latest News & Forecasts as of December 11, 2025

Arrowhead Pharmaceuticals (ARWR) Stock Near 52‑Week High After FDA Approval and New Alzheimer’s Trial: Latest News & Forecasts as of December 11, 2025

Arrowhead Pharmaceuticals shares surged to a new 52-week high above $72 on December 11 after the FDA approved its first drug, Redemplo, for familial chylomicronemia syndrome. The stock has climbed from the low-$40s to around $70 in a month, pushing market value to $9.6 billion, up over 300% year-over-year. The company also received an FDA Breakthrough Therapy designation and launched its first Alzheimer’s trial.
11 December 2025
··
Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus

Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus

Immunovant shares rose 9% to $25.75 Thursday after the company announced a $550 million common stock offering to fund development and possible launch of its lead drug, IMVT‑1402, for Graves’ disease. The offering priced at $21 per share, an 11% discount, and is expected to close December 12. Roivant Sciences will participate. Immunovant’s market value reached about $4 billion.
11 December 2025
····
Arcellx (ACLX) Stock Surges on Anito-cel Breakthrough Data as Analysts Boost Price Targets – December 9, 2025

Arcellx (ACLX) Stock Surges on Anito-cel Breakthrough Data as Analysts Boost Price Targets – December 9, 2025

Arcellx shares closed at $72.08 on December 9, down 2.7% after surging 13.6% pre-market on positive Phase 2 data for its multiple myeloma therapy anito-cel at ASH 2025. The iMMagine-1 study showed a 96% overall response rate and no delayed neurotoxicities in 117 heavily pretreated patients. Analysts maintain a “Strong Buy” consensus and anticipate a 2026 commercial launch.
9 December 2025
··
Praxis Precision Medicines (PRAX) Soars on FDA Momentum and 760-Dollar Target: December 9, 2025 Stock Deep Dive

Praxis Precision Medicines (PRAX) Soars on FDA Momentum and 760-Dollar Target: December 9, 2025 Stock Deep Dive

Praxis Precision Medicines shares traded near $265 on December 9, 2025, up over 500% in three months and close to a 52-week high of $278, giving the company a $6.6 billion market cap. The surge followed positive Phase 3 results for ulixacaltamide in essential tremor, new bullish analyst targets, and increased volatility after a short-seller attack.
9 December 2025
·
1 … 9 10 11 12 13 … 19

Stock Market Today

  • SpaceX Set to Join Nasdaq 100, Potential $4.3 Billion Market Boost for SPCX Stock
    June 28, 2026, 8:05 AM EDT. SpaceX ($SPCX), Elon Musk's aerospace and artificial intelligence firm, will join the Nasdaq 100 index on July 7. Inclusion in this key benchmark, which tracks the largest non-financial companies on the Nasdaq stock exchange, could trigger significant passive buying as index funds adjust holdings. Analysts estimate this shift may inject approximately $4.3 billion of demand into SPCX stock. This move underscores SpaceX's growing market footprint following its direct listing and highlights ongoing investor interest in the aerospace and technology sectors.

Latest articles

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 28.06.2026

28 June 2026
LIVEMarkets rolling coverageStarted: June 28, 2026, 4:00 AM EDTUpdated: June 28, 2026, 8:12 AM EDT SpaceX Set to Join Nasdaq 100, Potential $4.3 Billion Market Boost for SPCX Stock June 28, 2026, 8:05 AM EDT. SpaceX ($SPCX), Elon Musk’s aerospace and artificial intelligence firm, will join the Nasdaq 100 index on July 7. Inclusion in this key benchmark, which tracks the largest non-financial companies on the Nasdaq stock exchange, could trigger significant passive buying as index funds adjust holdings. Analysts estimate this shift may inject approximately $4.3 billion of demand into SPCX stock. This move underscores SpaceX’s growing market footprint
Go toTop